- Home
- MIST
as 11-05-2025 4:00pm EST
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Upcoming Earnings Alert:
Get ready for potential market movements as Milestone Pharmaceuticals Inc. MIST prepares to release earnings report on 11 Nov 2025.
| Founded: | 2003 | Country: | Canada |
| Employees: | N/A | City: | MONTREAL |
| Market Cap: | 163.2M | IPO Year: | N/A |
| Target Price: | $6.33 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $2.75 | Next Earning Date: | 11-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Milestone Pharmaceuticals Inc. News
MIST Breaking Stock News: Dive into MIST Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
3 days ago
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
GlobeNewswire
a month ago
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
MT Newswires
5 months ago
Milestone Pharmaceuticals Files Response to FDA for Cardamyst Nasal Spray
GlobeNewswire
5 months ago
Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting
GlobeNewswire
5 months ago
Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Zacks
5 months ago
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
Associated Press Finance
6 months ago
Milestone Pharmaceuticals: Q1 Earnings Snapshot
Compare MIST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MIST Milestone Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.